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of therapy (WBRT, systemic, and 
intra-CSF chemotherapy), a therapeu-
tic strategy, which the authors con-
clude, results in best outcomes.
The study was unclear as to how 
determinations of CSF abnormalities 
were made (dichotomous or continu-
ous variable), which according to the 
authors contention, impact survival 
independent of treatment. Nonspecific 
CSF abnormalities likely reflect CNS 
tumor burden more closely correlated 
with magnetic resonance imaging–
defined disease. The authors posit that 
ventriculo-peritoneal shunting is asso-
ciated with improved survival, which 
seems counterintuitive because such 
patients by definition are poor can-
didates for intra-CSF chemotherapy 
because of CSF compartmentalization. 
WBRT in isolation has been shown to 
be of limited benefit in patients with 
NSCLC and LM.5 LM is a neuraxis dis-
ease, with CSF dynamically circulating 
through brain and spine compartments. 
Consequently, it is not surprising that 
treatment of only a single CSF com-
partment with WBRT does not impact 
survival.
The statement that intra-CSF 
chemotherapy, WBRT, and epidermal 
growth factor receptor inhibitors, but 
not cytotoxic chemotherapy, with recog-
nized limited CNS penetration improves 
survival in patients with NSCLC and 
LM seems overreaching, given the chal-
lenges of a retrospective study and lack 
of appropriate controls, which necessar-
ily results in treatment-selection bias. 
As the authors indicate, management of 
solid tumor-related LM remains chal-
lenging because of a paucity of prospec-
tive trials and consequently the lack of 
standardization in LM-related treatment 
that is evidenced based.
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patients with LM defined by positive 
cerebrospinal fluid (CSF) cytology 
were included. Consequently, the study 
cohort was heterogenous with respect to 
identified LM-prognostic features (the 
presence or absence of radiographic 
bulky disease, carcinomatous encepha-
lopathy, performance status, CSF flow 
disruption, and burden of systemic 
disease), and therefore, it was unclear 
how many patients could be considered 
as favorable risk and LM-treatment 
appropriate.2,3 Strikingly different than 
the literature, the current study had a 
high incidence of LM at diagnosis of 
NSCLC (17%), a near-uniform concor-
dance of positive CSF cytology (100%) 
and magnetic resonance imaging find-
ings consistent with LM (94%), a high 
incidence of hydrocephalus (17%), lack 
of spine LM-related disease, and a high 
incidence of brain metastasis (66%).4
Because of the retrospective 
nature of the study, there were no a 
priori determinants of treatment such 
that treatment was defined individu-
ally, without apparent standardization 
making cross-comparisons between 
treatment groups problematic. There 
was no characterization before 
intra-CSF chemotherapy of whether 
patients underwent radioisotope CSF 
flow studies, to determine CSF com-
partmentalization because of LM that 
would compromise intra-CSF drug 
distribution. Although 66% of all the 
patients manifested brain metasta-
sis, only 32% received whole-brain 
radiotherapy (WBRT). Furthermore, 
there was no mention of administer-
ing spine radiotherapy for symptom-
atic or radiographically bulky disease 
in spine. Table 3 suggests that 13% of 
patients received supportive care (no 
explanation as to why), 12% were not 
treated with intra-CSF chemotherapy 
(again no explanation as to why), and 
only 12% received all three modalities 
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Lee et al.1 are to be congratulated for their analysis of patients with 
non–small-cell lung cancer (NSCLC) 
and leptomeningeal metastases (LM). 
Several aspects regarding the study 
warrant commentary.
First, this was a single-institu-
tion retrospective study, in which all 
Copyright © 2013 by the International Association 
for the Study of Lung Cancer
ISSN: 1556-0864/13/0807-0e65
abdominopelvic or peritoneal dis-
ease, and contralateral pleural disease, 
is classified as a distant recurrence. 
The aims of this classification are not 
only to convey the mechanism of pro-
gression but also to clarify options 
for salvage therapy. Further studies 
comparing outcomes in patients with 
marginal recurrences versus removed 
distant metastases will provide further 
enlightenment regarding the optimal 
manner in which to allocate and treat 
this distinct group of patients.
REFERENCES
 1. Agarwal PP, Seely JM, Matzinger FR, et al. 
Pleural mesothelioma: sensitivity and inci-
dence of needle track seeding after image-
guided biopsy versus surgical biopsy. Radiol 
2006; 241:589–94.
 2. Chen F, Yoshizawa A, Okubo K, Date H. 
Tumor extension along chest wall tract after 
diagnostic intervention in malignant pleural 
mesothelioma. Interact Cardiovasc Thorac 
Surg 2011; 12:1060–1062.
Daniel Gomez, MD
Anne Tsao, MD
David Rice, MD
Departments of Radiation Oncology
Division of Radiation Oncology,
Thoracic/Head and Neck Medical 
Oncology
Division of Cancer Medicine, and 
Thoracic and Cardiovascular Surgery
Division of Surgery
MD Anderson Cancer Center
University of Texas
Houston, TX
e67Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology®  •  Volume 8, Number 7, July 2013 Letters to the Editor
REFERENCES
 1. Lee SJ, Lee JI, Nam DH, et al. Leptomeningeal 
carcinomatosis in non-small-cell lung can-
cer patients: impact on survival and cor-
related prognostic factors. J Thorac Oncol 
2013;8:185–191.
 2. Brem SS, Bierman PJ, Brem H, et al.; 
National Comprehensive Cancer Network. 
Central nervous system cancers. J Natl 
Compr Canc Netw 2011;9:352–400.
 3. Chamberlain MC, Kormanik PA. Prognostic 
significance of coexistent bulky metastatic 
central nervous system disease in patients 
with leptomeningeal metastases. Arch Neurol 
1997;54:1364–1368.
 4. Chamberlain MC, Glantz M, Groves MD, 
Wilson WH. Diagnostic tools for neoplastic 
meningitis: detecting disease, identifying patient 
risk, and determining benefit of treatment. 
Semin Oncol 2009;36(4 Suppl 2):S35–S45.
Interpretation  
of Anti-ALK  
Immunohistochemistry 
Results
Address for correspondence: Kengo Takeuchi, 
MD, PhD, Pathology Project for Molecular 
Targets, The Cancer Institute, Japanese 
Foundation for Cancer Research, 3-8-31 
Ariake, Koto, Tokyo 135–8550, Japan. 
E-mail: kentakeuchi-tky@umin.net
Disclosure: The author is serving as an academic 
consultant for Nichirei Bioscience.
Copyright © 2013 by the International Association 
for the Study of Lung Cancer
ISSN: 1556-0864/13/0807-0e66In their report,1 Conklin et al. com-pared five antianaplastic lymphoma 
FIGURE 1.  ALK iAEP IHC in lung cancers with or without ALK fusion genes. Expression of ALK fusion protein is dependent on the 
promoter-enhancer activity of ALK partner genes, including EML4, which are usually housekeeping genes. In ALK fusion-positive 
tumors, therefore, all tumor cells are immunostained for the ALK kinase domain in IHC using anti-ALK antibody directed to the 
kinase domain, when stained appropriately by using a highly sensitive method, such as iAEP. All the cancer cells in an EML4–ALK-
positive lung cancer express EML4-ALK protein (A). Some lung cancer cases (<1%) may express full length ALK. In such a case, the 
staining intensity usually varies from cell to cell, showing staining heterogeneity. This heterogeneity is probably because ALK expres-
sion in these cases is physiological, as in normal nerve cells, and because the ALK promoter-enhancer activity varies among cells. 
ALK rearrangement-negative small-cell carcinoma (B), large-cell neuroendocrine carcinoma (C), and poorly differentiated carcinoma 
(squamous cell carcinoma in this case, D) of lung may sometimes express the full length ALK, and the staining pattern is usually 
heterogeneous. IHC, immunohistochemistry; ALK, anaplastic lymphoma kinase; iAEP, intercalated antibody-enhanced polymer.
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kinase immunohistochemistry (ALK 
IHC) systems. I agree with their conclu-
sion that IHC is reliable for detection of 
ALK rearrangement; however, I would 
like to comment on their interpretation 
of individual results.
